Lung Cancer Trial, Recruiting NCT07488507 Sponsor: Third Military Medical University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07488507
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have at least one abnormal area (lesion) in the chest region between the lungs, measuring at least 10mm, confirmed by a detailed CT scan
  • People who have not previously had a biopsy of this chest region and need one to find out what is causing the abnormality or to identify its exact type — and who fall into at least one of these groups: suspected lung cancer assessed by two senior doctors; confirmed lung cancer that requires further assessment of spread; or lung cancer that has come back after previous treatment
  • People who have completed all required pre-procedure tests and examinations (such as heart scans and specialised blood vessel imaging) to check that the procedure is safe for them
  • People who are able to understand the study and are willing to sign a written consent form

Who may not be able to join:

  • People with serious heart or lung disease, blood clotting problems, coughing up large amounts of blood, poor tolerance to anaesthesia, or any other reason that makes the bronchoscopy procedure unsafe for them
  • People in whom the abnormal area could not be located during the procedure, even after more than 20 minutes of attempts
  • People whose lesion is found to be a fluid-filled sac (cyst) or an abscess (pocket of infection)
  • People with a mental illness, severe anxiety-related condition, or any other condition that means they are unable to give informed consent
  • People who have taken part in another clinical trial in the past 3 months
  • People considered by the trial team to be unsuitable for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 18885230175

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Third Military Medical University
Registry
ClinicalTrials.gov
Start date
20 March 2026
Est. completion
1 March 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Diagnostic yield for lung cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov